New obesity drug HRS9531 takes on semaglutide in major trial
NCT ID NCT07285902
First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests a new drug called HRS9531 against an existing weight-loss drug, semaglutide, in 572 adults with obesity. Participants receive weekly injections for 52 weeks to see which drug works better for weight loss. The goal is to find a more effective treatment option for obesity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiness PLA General Hospital
Beijing, Beijing Municipality, 100853, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
Conditions
Explore the condition pages connected to this study.